1. Home
  2. FG vs CELC Comparison

FG vs CELC Comparison

Compare FG & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo F&G Annuities & Life Inc.

FG

F&G Annuities & Life Inc.

HOLD

Current Price

$28.53

Market Cap

3.8B

Sector

Finance

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$118.92

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FG
CELC
Founded
1959
2011
Country
United States
United States
Employees
1173
N/A
Industry
Life Insurance
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.1B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
FG
CELC
Price
$28.53
$118.92
Analyst Decision
Hold
Strong Buy
Analyst Count
2
9
Target Price
$31.00
$112.56
AVG Volume (30 Days)
528.3K
654.3K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
3.49%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.94
N/A
Revenue Next Year
$5.51
$720.19
P/E Ratio
$8.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.57
$9.64
52 Week High
$36.70
$129.09

Technical Indicators

Market Signals
Indicator
FG
CELC
Relative Strength Index (RSI) 69.31 50.85
Support Level $27.44 $99.38
Resistance Level $29.63 N/A
Average True Range (ATR) 0.80 7.17
MACD 0.23 -0.44
Stochastic Oscillator 91.06 54.80

Price Performance

Historical Comparison
FG
CELC

About FG F&G Annuities & Life Inc.

F&G Annuities & Life Inc is a provider of insurance solutions serving retail annuity and life customers as well as institutional clients. Through its insurance subsidiaries, including FGL Insurance and Fidelity & Guaranty Life Insurance Company of New York it markets a broad portfolio of deferred annuities (fixed indexed annuities (FIAs) and multi-year guarantee annuities (MYGAs) or other fixed rate annuities), immediate annuities, indexed universal life (IUL) insurance, funding agreements through funding agreement-backed notes issuances and the Federal Home Loan Bank of Atlanta (FHLB)), and pension risk transfer (PRT) solutions.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: